Funding Overview
<cite index="6-3">Chai Discovery, the company engineering artificial intelligence (AI) models to discover new molecules, announced a $400M Series C fundraise on July 14, 2026.</cite> <cite index="5-3">The round, which values the company at $3.8B, was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension.</cite> <cite index="5-4,5-5">New investors Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, and Avra Capital joined the round, as did existing backers Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite.</cite>
Valuation Trajectory
<cite index="2-1">The San Francisco-based startup, founded in March 2024, closed the round at a $3.8 billion valuation, roughly triple the $1.3 billion it was worth just seven months earlier.</cite> <cite index="8-8,8-9">The raise takes Chai's total funding above $600M in approximately eleven months, following a $70M Series A in mid-2025 and a $130M Series B at a $1.3B valuation in December 2025.</cite>
Technology and Model Progression
<cite index="9-11">Chai Discovery develops AI models that accelerate pre-clinical drug discovery by predicting and reprogramming molecular interactions.</cite> <cite index="13-18,13-19">Rather than screening vast libraries of existing molecules, Chai uses generative AI to design new antibodies and proteins from scratch, tuned to a disease target before they reach a laboratory.</cite>
<cite index="5-7">Chai-2, released in 2025, was the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates, representing a step-change over prior computational methods.</cite> <cite index="5-6">Its latest model, Chai-3, materially improves target success rates and binding affinity compared to its predecessor, producing antibodies that bind substantially more tightly to intended targets.</cite>
Commercial Deployments
<cite index="13-24,13-25">Chai says its models are deployed at Eli Lilly, Pfizer, and Novartis, and the company added a collaboration with immunology firm argenx concurrent with the funding announcement.</cite> <cite index="9-12">The platform enables pharmaceutical and life sciences companies to design better therapeutics faster, bringing greater precision and predictability to drug development, particularly for hard-to-drug and previously undruggable targets.</cite>
Founding Team
<cite index="17-5">Chai was founded in 2024 by Joshua Meier, who previously worked at AI drug discovery firm Absci, Facebook AI, and OpenAI; Jack Dent, former engineering and product leader at Stripe; and AI researchers Matthew McPartlon and Jacques Boitreaud.</cite> <cite index="17-6">Former Pfizer Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., responsible for advancing 150 molecules into clinical trials and delivering 36 approved medicines, serves on the company's board of directors.</cite>
Investor Rationale
<cite index="4-3">For investors, the financing reflects growing confidence that AI is transitioning from an experimental tool to a core component of pharmaceutical research.</cite> <cite index="10-5">Chief Executive Joshua Meier stated that "AI drug discovery has moved from promise to deployment," with Chai's models already enabling partners to design better molecules and move faster against difficult targets.</cite> <cite index="1-9">Chai Discovery plans to use the capital to further accelerate its research and development and expand the deployment of its AI-driven molecular design platform within the pharmaceutical and life sciences sectors.</cite>